After more than three decades of working with Fortune 1000 leaders, I’ve learned one truth that never fades: scale doesn’t guarantee safety. Even the most dominant players can be blindsided—by new entrants, shifting customer expectations, or technologies that rewrite the…

AI has transformed how we collect and analyze customer feedback — faster sentiment analysis, automated text clustering, predictive churn models. It’s powerful, but also perilous if used without context. Because while AI can detect patterns, it can’t detect meaning yet….

For years, executives have asked me the same question in one form or another: “How do I prove that Competitive Intelligence is worth the investment?” It’s a fair question. CI often delivers its biggest wins behind the scenes by shaping…

Pricing assessments have become one of the most frequent requests I get in the competitive intelligence space, and for good reasons. These projects aren’t like the usual qualitative intel-gathering exercises. They’re deep, data-driven, and if done right, can directly influence…

Over the years, I’ve seen Voice of Customer (VOC) perception studies evolve from “nice-to-haves” into must-have tools, especially for competitive intelligence teams. Yes, we all want to know what our competitors are doing. But here’s the truth: what customers think…

I still remember when immuno-oncology first started making waves. The buzz around checkpoint inhibitors was electric—PD-1, PD-L1, CTLA-4—suddenly, we were talking about cancer therapies that could unlock the immune system instead of just targeting the tumor. Fast forward a decade,…

As global trade dynamics shift yet again, the pharmaceutical industry is bracing for impact. Recent tariff developments—particularly the reintroduction of sweeping U.S. import duties—are prompting executives across healthcare and life sciences to revisit their sourcing strategies and cost structures. But…

When I first started working in the rare disease and gene therapy space, I thought the science would be the hardest part to wrap my head around. And don’t get me wrong—it’s complex. But what I didn’t fully appreciate at…

I’ll admit it—there was a time when neuroscience felt like a graveyard of pharma ambitions. I remember the wave of program terminations, the clinical failures, and the retreat from Alzheimer’s and Parkinson’s pipelines that felt almost industry wide. For a…